• Je něco špatně v tomto záznamu ?

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway

J. Pencik, C. Philippe, M. Schlederer, E. Atas, M. Pecoraro, S. Grund-Gröschke, WJ. Li, A. Tracz, I. Heidegger, S. Lagger, K. Trachtová, M. Oberhuber, E. Heitzer, O. Aksoy, HA. Neubauer, B. Wingelhofer, A. Orlova, N. Witzeneder, T. Dillinger, E....

. 2023 ; 22 (1) : 133. [pub] 20230812

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, Research Support, U.S. Gov't, Non-P.H.S., práce podpořená grantem, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016575

Grantová podpora
R01 CA237027 NCI NIH HHS - United States
R01 CA240290 NCI NIH HHS - United States

Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN is one of the most frequently deleted genes in mPCa. Here we show a frequent genomic co-deletion of PTEN and STAT3 in liquid biopsies of patients with mPCa. Loss of Stat3 in a Pten-null mouse prostate model leads to a reduction of LKB1/pAMPK with simultaneous activation of mTOR/CREB, resulting in metastatic disease. However, constitutive activation of Stat3 led to high LKB1/pAMPK levels and suppressed mTORC1/CREB pathway, preventing mPCa development. Metformin, one of the most widely prescribed therapeutics against type 2 diabetes, inhibits mTORC1 in liver and requires LKB1 to mediate glucose homeostasis. We find that metformin treatment of STAT3/AR-expressing PCa xenografts resulted in significantly reduced tumor growth accompanied by diminished mTORC1/CREB, AR and PSA levels. PCa xenografts with deletion of STAT3/AR nearly completely abrogated mTORC1/CREB inhibition mediated by metformin. Moreover, metformin treatment of PCa patients with high Gleason grade and type 2 diabetes resulted in undetectable mTORC1 levels and upregulated STAT3 expression. Furthermore, PCa patients with high CREB expression have worse clinical outcomes and a significantly increased risk of PCa relapse and metastatic recurrence. In summary, we have shown that STAT3 controls mPCa via LKB1/pAMPK/mTORC1/CREB signaling, which we have identified as a promising novel downstream target for the treatment of lethal mPCa.

Almac Diagnostics Craigavon BT63 5QD UK

Biochemical Institute University of Kiel 24098 Kiel Germany

Center for Biomarker Research in Medicine 8010 Graz Austria

Center for Cooperative Research in Biosciences Basque Research and Technology Alliance 20850 Derio Spain

Central European Institute of Technology Masaryk University 60177 Brno Czech Republic

Christian Doppler Laboratory for Applied Metabolomics Medical University of Vienna 1090 Vienna Austria

Comprehensive Cancer Center Medical University of Vienna 1090 Vienna Austria

Department for Basic and Translational Oncology and Hematology Division Molecular Oncology and Hematology Karl Landsteiner University of Health Sciences 3500 Krems Austria

Department of Biosciences and Medical Biology Cancer Cluster Salzburg Paris Lodron University of Salzburg 5020 Salzburg Austria

Department of Laboratory Medicine Medical University of Vienna 1090 Vienna Austria

Department of Molecular Biotechnology and Health Sciences Molecular Biotechnology Center University of Turin 10126 Turin Italy

Department of Molecular Sciences Swedish University of Agricultural Sciences 75007 Uppsala Sweden

Department of Oncology University of Oxford Oxford OX37DQ UK

Department of Pathology Medical University Innsbruck 6020 Innsbruck Austria

Department of Pathology Medical University of Vienna 1090 Vienna Austria

Department of Pathology University of Cambridge Cambridge CB20QQ UK

Department of Pharmacology and Therapeutics Roswell Park Comprehensive Cancer Center Buffalo NY 14263 USA

Department of Urology Medical University Innsbruck 6020 Innsbruck Austria

Department of Urology Medical University of Vienna 1090 Vienna Austria

Division of Nuclear Medicine Department of Biomedical Imaging and Image Guided Therapy Medical University of Vienna 1090 Vienna Austria

Division Pharmacology Department of Pharmacology Physiology and Microbiology Karl Landsteiner University of Health Sciences 3500 Krems Austria

Experimental Therapeutics Graduate Program Roswell Park Comprehensive Cancer Center Buffalo NY 14203 USA

Institute for Research in Biomedicine Università Della Svizzera Italiana 6500 Bellinzona Switzerland

Institute of Animal Breeding and Genetics University of Veterinary Medicine Vienna 1210 Vienna Austria

Institute of Human Genetics Medical University of Graz 8010 Graz Austria

Institute of Medical Genetics and Genomics Faculty of Medicine Masaryk University Kamenice 5 62500 Brno Czech Republic

Institute of Pharmacology Center for Physiology and Pharmacology Medical University of Vienna 1090 Vienna Austria

Institute of Physiology Pathophysiology and Biophysics University of Veterinary Medicine 1210 Vienna Austria

Ludwig Boltzmann Institute Applied Diagnostics 1090 Vienna Austria

MLL Munich Leukemia Laboratory 81377 Munich Germany

Molecular and Cell Biology Laboratory The Salk Institute for Biological Studies La Jolla CA 92037 USA

Patrick G Johnston Centre for Cancer Research Queen's University Belfast Belfast BT71NN UK

School of Pharmacy University of Nottingham Nottingham NG7 2RD UK

Unit for Pathology of Laboratory Animals University of Veterinary Medicine Vienna 1210 Vienna Austria

Université Paris Cité INSERM UMR S1151 CNRS UMR S8253 Institut Necker Enfants Malades 75015 Paris France

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016575
003      
CZ-PrNML
005      
20231026105719.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12943-023-01825-8 $2 doi
035    __
$a (PubMed)37573301
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pencik, Jan $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria. jpencik@salk.edu $u Center for Biomarker Research in Medicine, 8010, Graz, Austria. jpencik@salk.edu $u Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, 92037, USA. jpencik@salk.edu $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090, Vienna, Austria. jpencik@salk.edu
245    10
$a STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway / $c J. Pencik, C. Philippe, M. Schlederer, E. Atas, M. Pecoraro, S. Grund-Gröschke, WJ. Li, A. Tracz, I. Heidegger, S. Lagger, K. Trachtová, M. Oberhuber, E. Heitzer, O. Aksoy, HA. Neubauer, B. Wingelhofer, A. Orlova, N. Witzeneder, T. Dillinger, E. Redl, G. Greiner, D. D'Andrea, JR. Östman, S. Tangermann, I. Hermanova, G. Schäfer, F. Sternberg, EE. Pohl, C. Sternberg, A. Varady, J. Horvath, D. Stoiber, TI. Malcolm, SD. Turner, EE. Parkes, B. Hantusch, G. Egger, S. Rose-John, V. Poli, S. Jain, CWD. Armstrong, G. Hoermann, V. Goffin, F. Aberger, R. Moriggl, A. Carracedo, C. McKinney, RD. Kennedy, H. Klocker, MR. Speicher, DG. Tang, AA. Moazzami, DM. Heery, M. Hacker, L. Kenner
520    9_
$a Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN is one of the most frequently deleted genes in mPCa. Here we show a frequent genomic co-deletion of PTEN and STAT3 in liquid biopsies of patients with mPCa. Loss of Stat3 in a Pten-null mouse prostate model leads to a reduction of LKB1/pAMPK with simultaneous activation of mTOR/CREB, resulting in metastatic disease. However, constitutive activation of Stat3 led to high LKB1/pAMPK levels and suppressed mTORC1/CREB pathway, preventing mPCa development. Metformin, one of the most widely prescribed therapeutics against type 2 diabetes, inhibits mTORC1 in liver and requires LKB1 to mediate glucose homeostasis. We find that metformin treatment of STAT3/AR-expressing PCa xenografts resulted in significantly reduced tumor growth accompanied by diminished mTORC1/CREB, AR and PSA levels. PCa xenografts with deletion of STAT3/AR nearly completely abrogated mTORC1/CREB inhibition mediated by metformin. Moreover, metformin treatment of PCa patients with high Gleason grade and type 2 diabetes resulted in undetectable mTORC1 levels and upregulated STAT3 expression. Furthermore, PCa patients with high CREB expression have worse clinical outcomes and a significantly increased risk of PCa relapse and metastatic recurrence. In summary, we have shown that STAT3 controls mPCa via LKB1/pAMPK/mTORC1/CREB signaling, which we have identified as a promising novel downstream target for the treatment of lethal mPCa.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a proteinkinasy aktivované AMP $x metabolismus $7 D055372
650    12
$a diabetes mellitus 2. typu $7 D003924
650    _2
$a mTORC1 $x metabolismus $7 D000076222
650    12
$a metformin $x farmakologie $7 D008687
650    _2
$a lokální recidiva nádoru $7 D009364
650    12
$a nádory prostaty $x genetika $x patologie $7 D011471
650    _2
$a transkripční faktor STAT3 $x genetika $x metabolismus $7 D050796
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Philippe, Cecile $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Schlederer, Michaela $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Atas, Emine $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Pecoraro, Matteo $u Institute for Research in Biomedicine, Università Della Svizzera Italiana, 6500, Bellinzona, Switzerland
700    1_
$a Grund-Gröschke, Sandra $u Department of Biosciences and Medical Biology, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, 5020, Salzburg, Austria
700    1_
$a Li, Wen Jess $u Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA $u Experimental Therapeutics Graduate Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA
700    1_
$a Tracz, Amanda $u Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA
700    1_
$a Heidegger, Isabel $u Department of Urology, Medical University Innsbruck, 6020, Innsbruck, Austria
700    1_
$a Lagger, Sabine $u Unit for Pathology of Laboratory Animals, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Trachtová, Karolína $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Central European Institute of Technology, Masaryk University, 60177, Brno, Czech Republic $u Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Oberhuber, Monika $u Center for Biomarker Research in Medicine, 8010, Graz, Austria
700    1_
$a Heitzer, Ellen $u Institute of Human Genetics, Medical University of Graz, 8010, Graz, Austria
700    1_
$a Aksoy, Osman $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Department for Basic and Translational Oncology and Hematology, Division Molecular Oncology and Hematology, Karl Landsteiner University of Health Sciences, 3500, Krems, Austria
700    1_
$a Neubauer, Heidi A $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Wingelhofer, Bettina $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Orlova, Anna $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Witzeneder, Nadine $u Department of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Dillinger, Thomas $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Redl, Elisa $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Greiner, Georg $u Department of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a D'Andrea, David $u Department of Urology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Östman, Johnny R $u Department of Molecular Sciences, Swedish University of Agricultural Sciences, 75007, Uppsala, Sweden
700    1_
$a Tangermann, Simone $u Unit for Pathology of Laboratory Animals, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Hermanova, Ivana $u Center for Cooperative Research in Biosciences, Basque Research and Technology Alliance (BRTA), 20850, Derio, Spain
700    1_
$a Schäfer, Georg $u Department of Pathology, Medical University Innsbruck, 6020, Innsbruck, Austria
700    1_
$a Sternberg, Felix $u Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, 1210, Vienna, Austria
700    1_
$a Pohl, Elena E $u Institute of Physiology, Pathophysiology and Biophysics, University of Veterinary Medicine, 1210, Vienna, Austria
700    1_
$a Sternberg, Christina $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Unit for Pathology of Laboratory Animals, University of Veterinary Medicine Vienna, 1210, Vienna, Austria $u Biochemical Institute, University of Kiel, 24098, Kiel, Germany
700    1_
$a Varady, Adam $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Horvath, Jaqueline $u Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Stoiber, Dagmar $u Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, 1090, Vienna, Austria $u Division Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, 3500, Krems, Austria
700    1_
$a Malcolm, Tim I $u Department of Pathology, University of Cambridge, Cambridge, CB20QQ, UK
700    1_
$a Turner, Suzanne D $u Department of Pathology, University of Cambridge, Cambridge, CB20QQ, UK $u Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Kamenice 5, 62500, Brno, Czech Republic
700    1_
$a Parkes, Eileen E $u Department of Oncology, University of Oxford, Oxford, OX37DQ, UK
700    1_
$a Hantusch, Brigitte $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Egger, Gerda $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria $u Ludwig Boltzmann Institute Applied Diagnostics, 1090, Vienna, Austria $u Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Rose-John, Stefan $u Biochemical Institute, University of Kiel, 24098, Kiel, Germany
700    1_
$a Poli, Valeria $u Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, 10126, Turin, Italy
700    1_
$a Jain, Suneil $u Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, BT71NN, UK
700    1_
$a Armstrong, Chris W D $u Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, BT71NN, UK
700    1_
$a Hoermann, Gregor $u MLL Munich Leukemia Laboratory, 81377, Munich, Germany
700    1_
$a Goffin, Vincent $u Université Paris Cité, INSERM UMR-S1151, CNRS UMR-S8253, Institut Necker Enfants Malades, 75015, Paris, France
700    1_
$a Aberger, Fritz $u Department of Biosciences and Medical Biology, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, 5020, Salzburg, Austria
700    1_
$a Moriggl, Richard $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria
700    1_
$a Carracedo, Arkaitz $u Center for Cooperative Research in Biosciences, Basque Research and Technology Alliance (BRTA), 20850, Derio, Spain
700    1_
$a McKinney, Cathal $u Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, BT71NN, UK $u Almac Diagnostics, Craigavon, BT63 5QD, UK
700    1_
$a Kennedy, Richard D $u Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, BT71NN, UK $u Almac Diagnostics, Craigavon, BT63 5QD, UK
700    1_
$a Klocker, Helmut $u Department of Urology, Medical University Innsbruck, 6020, Innsbruck, Austria
700    1_
$a Speicher, Michael R $u Institute of Human Genetics, Medical University of Graz, 8010, Graz, Austria
700    1_
$a Tang, Dean G $u Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA $u Experimental Therapeutics Graduate Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14203, USA
700    1_
$a Moazzami, Ali A $u Department of Molecular Sciences, Swedish University of Agricultural Sciences, 75007, Uppsala, Sweden
700    1_
$a Heery, David M $u School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK
700    1_
$a Hacker, Marcus $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090, Vienna, Austria
700    1_
$a Kenner, Lukas $u Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Center for Biomarker Research in Medicine, 8010, Graz, Austria. lukas.kenner@meduniwien.ac.at $u Unit for Pathology of Laboratory Animals, University of Veterinary Medicine Vienna, 1210, Vienna, Austria. lukas.kenner@meduniwien.ac.at $u Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, 1090, Vienna, Austria. lukas.kenner@meduniwien.ac.at
773    0_
$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 22, č. 1 (2023), s. 133
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37573301 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105714 $b ABA008
999    __
$a ok $b bmc $g 2000221 $s 1202937
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 22 $c 1 $d 133 $e 20230812 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245
GRA    __
$a R01 CA237027 $p NCI NIH HHS $2 United States
GRA    __
$a R01 CA240290 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace